哈藥股份(600664.SH):擬將約1.25億元資產劃轉至哈藥集團中藥有限公司
格隆匯7月26日丨哈藥股份(600664.SH)公吿,公司擬將公司所屬分公司哈藥集團中藥二廠(簡稱“中藥二廠”)和哈藥集團世一堂製藥廠(簡稱“世一堂”)賬面全部淨資產按基準日2021年6月30日的合計金額1.1084億元增資至哈藥集團中藥有限公司(簡稱“中藥公司”),淨資產增資的最後金額以交割日賬面價值為準。
公司將持有的哈藥集團世一堂飲片廠(簡稱“中藥飲片”)的全部股權增資給中藥公司,其股權價格以中藥飲片2021年6月30日的賬面淨資產1372萬元為基礎確定,股權增資的最終價格以交割日賬面價值為準。
據悉,本次股權轉讓事項經公司董事會審議通過之後,交易雙方將另行簽署股權轉讓協議。本次增資系哈藥股份內部資源整合,屬於內部生產經營資產調整,不會導致公司合併報表範圍發生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.